PT2235012E - Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina - Google Patents
Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina Download PDFInfo
- Publication number
- PT2235012E PT2235012E PT88656038T PT08865603T PT2235012E PT 2235012 E PT2235012 E PT 2235012E PT 88656038 T PT88656038 T PT 88656038T PT 08865603 T PT08865603 T PT 08865603T PT 2235012 E PT2235012 E PT 2235012E
- Authority
- PT
- Portugal
- Prior art keywords
- alkyl
- formula
- group
- compounds
- optionally substituted
- Prior art date
Links
- 150000005007 4-aminopyrimidines Chemical class 0.000 title description 3
- 229940119240 Histamine H4 receptor antagonist Drugs 0.000 title description 2
- 239000003396 histamine H4 receptor antagonist Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 457
- 125000000217 alkyl group Chemical group 0.000 claims description 231
- 125000000623 heterocyclic group Chemical group 0.000 claims description 183
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 165
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 118
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 110
- 229910052736 halogen Inorganic materials 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 69
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 59
- 125000003118 aryl group Chemical group 0.000 claims description 58
- 125000001424 substituent group Chemical group 0.000 claims description 58
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 125000002619 bicyclic group Chemical group 0.000 claims description 54
- 150000002367 halogens Chemical class 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 47
- 229910052799 carbon Inorganic materials 0.000 claims description 45
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 42
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 41
- 125000005842 heteroatom Chemical group 0.000 claims description 39
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 32
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 30
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 26
- 125000002950 monocyclic group Chemical group 0.000 claims description 26
- 208000026935 allergic disease Diseases 0.000 claims description 25
- 208000027866 inflammatory disease Diseases 0.000 claims description 24
- 208000002193 Pain Diseases 0.000 claims description 23
- 230000000172 allergic effect Effects 0.000 claims description 23
- 230000001900 immune effect Effects 0.000 claims description 23
- 208000026278 immune system disease Diseases 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000003386 piperidinyl group Chemical group 0.000 claims description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 17
- 125000003725 azepanyl group Chemical group 0.000 claims description 16
- 125000002393 azetidinyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910021529 ammonia Inorganic materials 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 14
- 102000004187 Histamine H4 receptors Human genes 0.000 claims description 13
- 108090000796 Histamine H4 receptors Proteins 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 229910003827 NRaRb Inorganic materials 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- -1 2-iodoethyl Chemical group 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
- 125000001153 fluoro group Chemical group F* 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000000203 mixture Substances 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000002904 solvent Substances 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 37
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- 208000004454 Hyperalgesia Diseases 0.000 description 13
- 208000035154 Hyperesthesia Diseases 0.000 description 13
- 229960001340 histamine Drugs 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
- 206010052779 Transplant rejections Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 206010025135 lupus erythematosus Diseases 0.000 description 11
- 201000006417 multiple sclerosis Diseases 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 206010012438 Dermatitis atopic Diseases 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 208000021722 neuropathic pain Diseases 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010058019 Cancer Pain Diseases 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 6
- 206010013774 Dry eye Diseases 0.000 description 6
- 206010065390 Inflammatory pain Diseases 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 6
- 208000004550 Postoperative Pain Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 206010039085 Rhinitis allergic Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 208000024780 Urticaria Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 201000010105 allergic rhinitis Diseases 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 208000009935 visceral pain Diseases 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- UPVBKNZVOJNQKE-UHFFFAOYSA-N 2,6-dichloropyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(Cl)=N1 UPVBKNZVOJNQKE-UHFFFAOYSA-N 0.000 description 5
- KKXGAZSMMLZRHZ-SNVBAGLBSA-N 6-[(3r)-3-(methylamino)pyrrolidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CC(C)C)=N1 KKXGAZSMMLZRHZ-SNVBAGLBSA-N 0.000 description 5
- QRBVUFXEMHNIDB-UHFFFAOYSA-N 6-[3-(methylamino)azetidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(CC(C)C)=N1 QRBVUFXEMHNIDB-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- LNEKYCVFCBUNCS-SNVBAGLBSA-N 2-(2,2-dimethylpropyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CC(C)(C)C)=N1 LNEKYCVFCBUNCS-SNVBAGLBSA-N 0.000 description 4
- BPOJPENGALUIOB-UHFFFAOYSA-N 2-(2,2-dimethylpropyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(CC(C)(C)C)=N1 BPOJPENGALUIOB-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 102000000543 Histamine Receptors Human genes 0.000 description 4
- 108010002059 Histamine Receptors Proteins 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
- QBQNMPRYVGHOOO-CYBMUJFWSA-N 2-(2-cyclopentylethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CCC2CCCC2)=N1 QBQNMPRYVGHOOO-CYBMUJFWSA-N 0.000 description 3
- DZDJMOFABHXXNK-UHFFFAOYSA-N 6-(3-aminoazetidin-1-yl)-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound CC(C)CC1=NC(N)=CC(N2CC(N)C2)=N1 DZDJMOFABHXXNK-UHFFFAOYSA-N 0.000 description 3
- QRPGPMNGTXYKCU-SECBINFHSA-N 6-[(3r)-3-aminopyrrolidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound CC(C)CC1=NC(N)=CC(N2C[C@H](N)CC2)=N1 QRPGPMNGTXYKCU-SECBINFHSA-N 0.000 description 3
- DSNRKDHWJGBCID-UHFFFAOYSA-N 6-[3-methyl-3-(methylamino)azetidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound C1C(NC)(C)CN1C1=CC(N)=NC(CC(C)C)=N1 DSNRKDHWJGBCID-UHFFFAOYSA-N 0.000 description 3
- DYJSOJJJSNFKDO-UHFFFAOYSA-N CNC1CNC1N Chemical compound CNC1CNC1N DYJSOJJJSNFKDO-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001016858 Homo sapiens Histamine H4 receptor Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 102000051809 human HRH4 Human genes 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UEAYAIWNQQWSBK-GFCCVEGCSA-N (3r)-1-benzyl-n-methylpyrrolidin-3-amine Chemical compound C1[C@H](NC)CCN1CC1=CC=CC=C1 UEAYAIWNQQWSBK-GFCCVEGCSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- XZCRSAHYXMATAT-CYBMUJFWSA-N 2-(cyclohexylmethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CC2CCCCC2)=N1 XZCRSAHYXMATAT-CYBMUJFWSA-N 0.000 description 2
- KDRAYASEONFQQK-UHFFFAOYSA-N 2-(cyclohexylmethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(CC2CCCCC2)=N1 KDRAYASEONFQQK-UHFFFAOYSA-N 0.000 description 2
- BRHPOXZLZMXWER-SNVBAGLBSA-N 2-(cyclopropylmethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CC2CC2)=N1 BRHPOXZLZMXWER-SNVBAGLBSA-N 0.000 description 2
- ZQMQPMUYWSFTNQ-UHFFFAOYSA-N 2-(cyclopropylmethyl)-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(CC2CC2)=N1 ZQMQPMUYWSFTNQ-UHFFFAOYSA-N 0.000 description 2
- AQOWIKZJHPQYIT-CYBMUJFWSA-N 2-[(4-fluorophenyl)methyl]-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(CC=2C=CC(F)=CC=2)=N1 AQOWIKZJHPQYIT-CYBMUJFWSA-N 0.000 description 2
- SLYOOEZUVJZQTC-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(CC=2C=CC(F)=CC=2)=N1 SLYOOEZUVJZQTC-UHFFFAOYSA-N 0.000 description 2
- CNLDJMBFVFNWQQ-SECBINFHSA-N 2-tert-butyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C(C)(C)C)=N1 CNLDJMBFVFNWQQ-SECBINFHSA-N 0.000 description 2
- YIZAEQSSHWXTCF-UHFFFAOYSA-N 2-tert-butyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C(C)(C)C)=N1 YIZAEQSSHWXTCF-UHFFFAOYSA-N 0.000 description 2
- SYMBJSDZFDGMCY-UHFFFAOYSA-N 3-methylbutanimidamide;hydrochloride Chemical compound Cl.CC(C)CC(N)=N SYMBJSDZFDGMCY-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KXSAVRSIQRTDOC-SECBINFHSA-N 6-[(3r)-3-(methylamino)pyrrolidin-1-yl]-2-propan-2-ylpyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C(C)C)=N1 KXSAVRSIQRTDOC-SECBINFHSA-N 0.000 description 2
- XRNXNGNDYYVSJU-UHFFFAOYSA-N 6-[3-(methylamino)azetidin-1-yl]-2-propan-2-ylpyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C(C)C)=N1 XRNXNGNDYYVSJU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DSDCDMKASWVZHI-UHFFFAOYSA-M zinc;2-methanidylpropane;bromide Chemical compound Br[Zn+].CC(C)[CH2-] DSDCDMKASWVZHI-UHFFFAOYSA-M 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- PVQXRYTXOATJFJ-UHFFFAOYSA-N 1-benzhydryl-n,3-dimethylazetidin-3-amine Chemical compound C1C(NC)(C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 PVQXRYTXOATJFJ-UHFFFAOYSA-N 0.000 description 1
- FQFKVNTZBGKHLL-UHFFFAOYSA-N 1-benzhydryl-n-methylazetidin-3-amine Chemical compound C1C(NC)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FQFKVNTZBGKHLL-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- HJNBCVWWPLRZLC-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;oxolane Chemical compound C1CCOC1.CN1CCCC1=O HJNBCVWWPLRZLC-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- NLMBJXRBYZYYSC-CYBMUJFWSA-N 2-(2-cyclopentylethynyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C#CC2CCCC2)=N1 NLMBJXRBYZYYSC-CYBMUJFWSA-N 0.000 description 1
- LEKFRNFLTCMURJ-UHFFFAOYSA-N 2-(2-methylpropyl)pyrimidin-4-amine Chemical compound CC(C)CC1=NC=CC(N)=N1 LEKFRNFLTCMURJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- PEAFAIMBSQOGBJ-SNVBAGLBSA-N 2-cyclobutyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C2CCC2)=N1 PEAFAIMBSQOGBJ-SNVBAGLBSA-N 0.000 description 1
- MYQMPVUYULVNIJ-UHFFFAOYSA-N 2-cyclobutyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C2CCC2)=N1 MYQMPVUYULVNIJ-UHFFFAOYSA-N 0.000 description 1
- BVXCDIAVPKCGFO-GFCCVEGCSA-N 2-cyclohexyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C2CCCCC2)=N1 BVXCDIAVPKCGFO-GFCCVEGCSA-N 0.000 description 1
- GDTVSOUBBZVXKE-UHFFFAOYSA-N 2-cyclohexyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C2CCCCC2)=N1 GDTVSOUBBZVXKE-UHFFFAOYSA-N 0.000 description 1
- RPLHEALRFOZPFW-LLVKDONJSA-N 2-cyclopentyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C2CCCC2)=N1 RPLHEALRFOZPFW-LLVKDONJSA-N 0.000 description 1
- NFIIHIBPRLSPDQ-UHFFFAOYSA-N 2-cyclopentyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C2CCCC2)=N1 NFIIHIBPRLSPDQ-UHFFFAOYSA-N 0.000 description 1
- VFGWJXCRWXZRHV-UHFFFAOYSA-N 2-cyclopropyl-4-hydroxy-1h-pyrimidin-6-one Chemical compound OC1=CC(O)=NC(C2CC2)=N1 VFGWJXCRWXZRHV-UHFFFAOYSA-N 0.000 description 1
- FALAPUJFNOYRNF-SECBINFHSA-N 2-cyclopropyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(C2CC2)=N1 FALAPUJFNOYRNF-SECBINFHSA-N 0.000 description 1
- BPOHNBUIIKQJHS-UHFFFAOYSA-N 2-cyclopropyl-6-[3-(methylamino)azetidin-1-yl]pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(C2CC2)=N1 BPOHNBUIIKQJHS-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- GGJZNRRFDCKJCD-UHFFFAOYSA-N 2-phenoxyethanimidamide Chemical compound NC(=N)COC1=CC=CC=C1 GGJZNRRFDCKJCD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- INTDGBJUITUUCN-UHFFFAOYSA-N 2-tert-butyl-4,6-dichloropyrimidine Chemical compound CC(C)(C)C1=NC(Cl)=CC(Cl)=N1 INTDGBJUITUUCN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NWMAYMXDONWXTE-UHFFFAOYSA-N 3-methylbutanimidamide Chemical compound CC(C)CC(N)=N NWMAYMXDONWXTE-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YSWBFLWKAIRHEI-UHFFFAOYSA-N 4,5-dimethyl-1h-imidazole Chemical compound CC=1N=CNC=1C YSWBFLWKAIRHEI-UHFFFAOYSA-N 0.000 description 1
- IRJXGGROVGQOCR-UHFFFAOYSA-N 4,6-dichloro-2-(2-methylpropyl)pyrimidine Chemical compound CC(C)CC1=NC(Cl)=CC(Cl)=N1 IRJXGGROVGQOCR-UHFFFAOYSA-N 0.000 description 1
- FZORPMVFFZNTNU-UHFFFAOYSA-N 4,6-dichloro-2-(cyclopropylmethyl)pyrimidine Chemical compound ClC1=CC(Cl)=NC(CC2CC2)=N1 FZORPMVFFZNTNU-UHFFFAOYSA-N 0.000 description 1
- VUDAVQBBQDZOLI-UHFFFAOYSA-N 4,6-dichloro-2-(phenoxymethyl)pyrimidine Chemical compound ClC1=CC(Cl)=NC(COC=2C=CC=CC=2)=N1 VUDAVQBBQDZOLI-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- UKGYXPQINPONGH-UHFFFAOYSA-N 4-chloro-2-(phenoxymethyl)pyrimidine Chemical compound ClC1=CC=NC(COC=2C=CC=CC=2)=N1 UKGYXPQINPONGH-UHFFFAOYSA-N 0.000 description 1
- GNRIZSOSSWDACM-UHFFFAOYSA-N 4-chloro-2-cyclopropylpyrimidine Chemical compound ClC1=CC=NC(C2CC2)=N1 GNRIZSOSSWDACM-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- KBKLCXNDZBKDDW-UHFFFAOYSA-N 4-hydroxy-2-(2-methylpropyl)-1h-pyrimidin-6-one Chemical compound CC(C)CC1=NC(O)=CC(O)=N1 KBKLCXNDZBKDDW-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- JNBDFQYQAOWYNX-GFCCVEGCSA-N 6-[(3r)-3-(methylamino)pyrrolidin-1-yl]-2-(phenoxymethyl)pyrimidin-4-amine Chemical compound C1[C@H](NC)CCN1C1=CC(N)=NC(COC=2C=CC=CC=2)=N1 JNBDFQYQAOWYNX-GFCCVEGCSA-N 0.000 description 1
- IQNZPCQDESUHFE-UHFFFAOYSA-N 6-[3-(methylamino)azetidin-1-yl]-2-(phenoxymethyl)pyrimidin-4-amine Chemical compound C1C(NC)CN1C1=CC(N)=NC(COC=2C=CC=CC=2)=N1 IQNZPCQDESUHFE-UHFFFAOYSA-N 0.000 description 1
- VWIXSUNRGQXMNB-UHFFFAOYSA-N 6-amino-2-(2-methylpropyl)-1h-pyrimidin-4-one Chemical compound CC(C)CC1=NC(N)=CC(O)=N1 VWIXSUNRGQXMNB-UHFFFAOYSA-N 0.000 description 1
- PUWYZNJGAFRDJX-UHFFFAOYSA-N 6-chloro-2-(2-cyclopentylethynyl)pyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(C#CC2CCCC2)=N1 PUWYZNJGAFRDJX-UHFFFAOYSA-N 0.000 description 1
- KJAMIJRGPFDVRV-UHFFFAOYSA-N 6-chloro-2-(2-methylpropyl)pyrimidin-4-amine Chemical compound CC(C)CC1=NC(N)=CC(Cl)=N1 KJAMIJRGPFDVRV-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- DCDOGNHJVZASMO-UHFFFAOYSA-N acetic acid;3-methylbutanimidamide Chemical compound CC(O)=O.CC(C)CC(N)=N DCDOGNHJVZASMO-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- RUARFZVAYUXNQM-UHFFFAOYSA-N azetidin-2-amine Chemical compound NC1CCN1 RUARFZVAYUXNQM-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- YRTJYDRUQDCJKA-UHFFFAOYSA-N cyclobutanecarboximidamide Chemical compound NC(=N)C1CCC1 YRTJYDRUQDCJKA-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006623 cyclooctylmethyl group Chemical group 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 125000004342 dicyclopropylmethyl group Chemical group [H]C1([H])C([H])([H])C1([H])C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- ZAKAONRTRWRIJT-UHFFFAOYSA-N ethyl 3-ethoxy-3-iminopropanoate Chemical compound CCOC(=N)CC(=O)OCC ZAKAONRTRWRIJT-UHFFFAOYSA-N 0.000 description 1
- HYMXUYQKXCHWDC-UHFFFAOYSA-N ethyl 3-ethoxy-3-iminopropanoate;hydrochloride Chemical compound Cl.CCOC(=N)CC(=O)OCC HYMXUYQKXCHWDC-UHFFFAOYSA-N 0.000 description 1
- TXVJSWLZYQMWPC-UHFFFAOYSA-N ethynylcyclopentane Chemical group C#CC1CCCC1 TXVJSWLZYQMWPC-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WYPGAZRNYWLYGQ-UHFFFAOYSA-N tert-butyl n-(1-benzhydrylazetidin-3-yl)-n-methylcarbamate Chemical compound C1C(N(C)C(=O)OC(C)(C)C)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 WYPGAZRNYWLYGQ-UHFFFAOYSA-N 0.000 description 1
- LHUFQYUQIUJJIB-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1CNC1 LHUFQYUQIUJJIB-UHFFFAOYSA-N 0.000 description 1
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 1
- YBCCTTBBUNOCEH-UHFFFAOYSA-N tert-butyl n-[1-(2-tert-butyl-6-chloropyrimidin-4-yl)azetidin-3-yl]-n-methylcarbamate Chemical compound C1C(N(C)C(=O)OC(C)(C)C)CN1C1=CC(Cl)=NC(C(C)(C)C)=N1 YBCCTTBBUNOCEH-UHFFFAOYSA-N 0.000 description 1
- IGNKVXHJLRKKAY-UHFFFAOYSA-N tert-butyl n-[1-[6-chloro-2-(2-methylpropyl)pyrimidin-4-yl]azetidin-3-yl]-n-methylcarbamate Chemical compound CC(C)CC1=NC(Cl)=CC(N2CC(C2)N(C)C(=O)OC(C)(C)C)=N1 IGNKVXHJLRKKAY-UHFFFAOYSA-N 0.000 description 1
- XYKYUXYNQDXZTD-MRVPVSSYSA-N tert-butyl n-methyl-n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)[C@@H]1CCNC1 XYKYUXYNQDXZTD-MRVPVSSYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07382006 | 2007-12-21 | ||
| US3153408P | 2008-02-26 | 2008-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2235012E true PT2235012E (pt) | 2013-08-28 |
Family
ID=39473347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT88656038T PT2235012E (pt) | 2007-12-21 | 2008-12-18 | Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8431580B2 (enExample) |
| EP (1) | EP2235012B1 (enExample) |
| JP (1) | JP5498396B2 (enExample) |
| KR (1) | KR101639819B1 (enExample) |
| CN (1) | CN101903385B (enExample) |
| AR (1) | AR069814A1 (enExample) |
| AU (1) | AU2008341678B2 (enExample) |
| BR (1) | BRPI0820779B8 (enExample) |
| CA (1) | CA2709650C (enExample) |
| CL (1) | CL2008003811A1 (enExample) |
| CY (1) | CY1114427T1 (enExample) |
| DK (1) | DK2235012T3 (enExample) |
| ES (1) | ES2430210T3 (enExample) |
| HR (1) | HRP20130918T1 (enExample) |
| IL (1) | IL206413A (enExample) |
| PE (1) | PE20091330A1 (enExample) |
| PL (1) | PL2235012T3 (enExample) |
| PT (1) | PT2235012E (enExample) |
| RU (1) | RU2489430C2 (enExample) |
| SI (1) | SI2235012T1 (enExample) |
| TW (1) | TWI429440B (enExample) |
| UA (1) | UA101963C2 (enExample) |
| WO (1) | WO2009080721A2 (enExample) |
| ZA (1) | ZA201005179B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| MY160526A (en) | 2008-12-22 | 2017-03-15 | Merck Patent Gmbh | Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| AU2010311378B2 (en) | 2009-10-29 | 2014-04-24 | Vectura Limited | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
| PE20121505A1 (es) * | 2009-12-23 | 2012-11-05 | Medicis Pharmaceutical Corp | Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina |
| US9688989B2 (en) | 2012-06-08 | 2017-06-27 | Sensorion | H4 receptor inhibitors for treating tinnitus |
| ES2946551T3 (es) * | 2017-10-17 | 2023-07-20 | Palau Pharma S L U | Síntesis de compuestos de 4-aminopirimidina |
| GB201817047D0 (en) | 2018-10-19 | 2018-12-05 | Heptares Therapeutics Ltd | H4 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2361869C2 (ru) * | 2002-02-05 | 2009-07-20 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Новые арил- и гетероарилпиперазины |
| EP1505064A1 (en) * | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
| WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| SMP200600024B (it) * | 2003-12-15 | 2006-07-19 | Almirall Prodesfarma Ag | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina |
| EP1888565B1 (en) * | 2005-04-11 | 2011-03-23 | Almirall, S.A. | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists |
| AU2006290715A1 (en) * | 2005-09-13 | 2007-03-22 | Palau Pharma, S.A. | 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity |
| WO2007084914A2 (en) * | 2006-01-17 | 2007-07-26 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
-
2008
- 2008-12-18 CA CA2709650A patent/CA2709650C/en active Active
- 2008-12-18 UA UAA201007805A patent/UA101963C2/ru unknown
- 2008-12-18 EP EP08865603.8A patent/EP2235012B1/en active Active
- 2008-12-18 DK DK08865603.8T patent/DK2235012T3/da active
- 2008-12-18 PT PT88656038T patent/PT2235012E/pt unknown
- 2008-12-18 KR KR1020107013477A patent/KR101639819B1/ko active Active
- 2008-12-18 TW TW097149462A patent/TWI429440B/zh active
- 2008-12-18 WO PCT/EP2008/067950 patent/WO2009080721A2/en not_active Ceased
- 2008-12-18 BR BRPI0820779A patent/BRPI0820779B8/pt active IP Right Grant
- 2008-12-18 CL CL2008003811A patent/CL2008003811A1/es unknown
- 2008-12-18 RU RU2010130418/04A patent/RU2489430C2/ru active
- 2008-12-18 ES ES08865603T patent/ES2430210T3/es active Active
- 2008-12-18 SI SI200831056T patent/SI2235012T1/sl unknown
- 2008-12-18 CN CN200880121970XA patent/CN101903385B/zh active Active
- 2008-12-18 PL PL08865603T patent/PL2235012T3/pl unknown
- 2008-12-18 HR HRP20130918AT patent/HRP20130918T1/hr unknown
- 2008-12-18 JP JP2010538738A patent/JP5498396B2/ja active Active
- 2008-12-18 AU AU2008341678A patent/AU2008341678B2/en active Active
- 2008-12-18 US US12/809,371 patent/US8431580B2/en active Active
- 2008-12-18 AR ARP080105539A patent/AR069814A1/es unknown
- 2008-12-19 PE PE2008002160A patent/PE20091330A1/es active IP Right Grant
-
2010
- 2010-06-16 IL IL206413A patent/IL206413A/en active IP Right Grant
- 2010-07-20 ZA ZA2010/05179A patent/ZA201005179B/en unknown
-
2013
- 2013-09-10 CY CY20131100781T patent/CY1114427T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2235012E (pt) | Derivados de 4-aminopirimidina como antagonistas de receptor h4 de histamina | |
| CA2953798C (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| AU2022217353B2 (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
| EP1928862A1 (en) | 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity | |
| WO2009077608A1 (en) | 2 -aminopyrimidine derivatives as histamine h4 antagonists | |
| WO2009068512A1 (en) | 2 -amino-pyrimidine derivatives as histamine h4 antagonists | |
| CA3181790A1 (en) | Amidopyrimidone derivatives | |
| RU2573828C2 (ru) | Производные аминоалкилпиримидина в качестве антагонистов h4 рецептора гистамина | |
| CN104557871A (zh) | 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途 | |
| WO2009115496A1 (en) | Furo [3, 2-d] pyrimidine derivatives as h4 receptor antagonists | |
| EP4380566A1 (en) | Methods of treating migraine with mnk inhibitors | |
| HK1149003B (en) | 4-aminopyrimidine derivatives as histamine h4 receptor antagonists | |
| WO2010094721A1 (en) | Piperidin-pyrimidine derivatives as antagonists of histamine h4 receptor | |
| HK1178162A (en) | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |